Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

145.31 -3.97 (-2.66%)

Official Closing Price Updated: 4:04 PM EDT, Sep 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Today 8:15 EDT

From Merck & Co., Inc.

Via Business Wire

Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor

September 28, 2026

From Merck & Co., Inc.

Via Business Wire

U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)

September 25, 2026

From Merck & Co., Inc.

Via Business Wire

Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema

September 24, 2026

From Merck & Co.

Via Business Wire

U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)

September 22, 2026

From Merck & Co., Inc.

Via Business Wire

Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan

September 21, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)

September 18, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV

September 18, 2026

From Merck & Co., Inc.

Via Business Wire

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance

September 10, 2026

Via Investor Brand Network

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

September 10, 2026

Via Investor Brand Network

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance

September 10, 2026

Via Investor Brand Network

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

September 10, 2026

From BioMedWire

Via GlobeNewswire

Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 08, 2026

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 02, 2026

From Merck & Co., Inc.

Via Business Wire

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

August 06, 2026

From Merck & Co., Inc.

Via Business Wire

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

August 04, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Announces Fourth-Quarter 2026 Dividend

July 29, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

July 24, 2026

From Merck & Co., Inc.

Via Business Wire

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

July 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

July 16, 2026

From Merck & Co., Inc.

Via Business Wire

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

July 15, 2026

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

July 15, 2026

From Merck & Co., Inc.

Via Business Wire

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

July 10, 2026

From Merck & Co., Inc.

Via Business Wire

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

July 01, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

June 29, 2026

From Merck & Co., Inc.

Via Business Wire

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

June 25, 2026

From Merck & Co., Inc.

Via Business Wire

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market

June 24, 2026

Via Investor Brand Network

The Quest to Repair What Multiple Sclerosis Takes Away

June 24, 2026

Via Investor Brand Network

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis

June 24, 2026

Via Investor Brand Network

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies

June 24, 2026

Via Investor Brand Network

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.